GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » SpectraScience Inc (GREY:SCIE) » Definitions » Altman Z-Score

SpectraScience (SpectraScience) Altman Z-Score : N/A (As of May. 17, 2024)


View and export this data going back to . Start your Free Trial

What is SpectraScience Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

SpectraScience has a Altman Z-Score of N/A, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for SpectraScience's Altman Z-Score or its related term are showing as below:


SpectraScience Altman Z-Score Historical Data

The historical data trend for SpectraScience's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SpectraScience Altman Z-Score Chart

SpectraScience Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -34.77 -29.93 -37.75 -45.75 -

SpectraScience Quarterly Data
Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of SpectraScience's Altman Z-Score

For the Medical Devices subindustry, SpectraScience's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SpectraScience's Altman Z-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, SpectraScience's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where SpectraScience's Altman Z-Score falls into.



SpectraScience Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

SpectraScience's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*-10.2562+1.4*-47.4286+3.3*-3.3415+0.6*0+1.0*0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Sep. 2017:
Total Assets was $1.22 Mil.
Total Current Assets was $0.31 Mil.
Total Current Liabilities was $12.81 Mil.
Retained Earnings was $-57.77 Mil.
Pre-Tax Income was -1.548 + -1.251 + -1.004 + -1.545 = $-5.35 Mil.
Interest Expense was -0.612 + -0.266 + -0.185 + -0.215 = $-1.28 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Market Cap (Today) was $0.00 Mil.
Total Liabilities was $14.25 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(0.313 - 12.805)/1.218
=-10.2562

X2=Retained Earnings/Total Assets
=-57.768/1.218
=-47.4286

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-5.348 - -1.278)/1.218
=-3.3415

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=0.000/14.246
=0

X5=Revenue/Total Assets
=0/1.218
=0

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

SpectraScience has a Altman Z-Score of N/A indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


SpectraScience  (GREY:SCIE) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


SpectraScience Altman Z-Score Related Terms

Thank you for viewing the detailed overview of SpectraScience's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


SpectraScience (SpectraScience) Business Description

Traded in Other Exchanges
N/A
Address
11568-11 Sorrento Valley Road, San Diego, CA, USA, 92121
SpectraScience Inc is a US based company focused on developing the WavSTAT Optical Biopsy System (WavSTAT). The WavSTAT employs a risk technology that optically illuminates tissue in real-time to distinguish between normal and pre-cancerous or cancerous tissue. The firm has developed a technology platform to determine if the tissue is normal, pre-cancerous or cancerous, without the need for a physical biopsy. The WavSTAT operates by using cool, safe UV laser light to optically illuminate and analyze tissue, enabling the physician to make a diagnosis during endoscopy when screening for cancer and, if warranted, to begin treatment during the same procedure. The group sells its product in the United States and Europe, of which majority of the sales revenue is derived from the United States.
Executives
Lowell Giffhorn officer: CFO 10875 KEMAH LANE, SAN DIEGO CA 92131
John Pappajohn director 1660 WALT WHITMAN ROAD, SUITE 105, MELVILLE NY 11747
Euclidsr Partners, L.p. 10 percent owner 45 ROCKEFELLER PLAZA, SUITE 3240, NEW YORK NY 10111
Euclidsr Associates, L.p. 10 percent owner 45 ROCKEFELLER PLAZA, SUITE 3240, NEW YORK NY 10111
Tommy G Thompson director 7711 CARONDELET, ST. LOUIS MO 63105

SpectraScience (SpectraScience) Headlines

No Headlines